Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Opinion

Impact of genetic diagnostics on drug development strategy

Nature Reviews Drug Discovery volume 5, pages 459–462 (2006)Cite this article

Abstract

Innovation in diagnostics will be essential for the successful adoption of personalized medicine and will also have a major impact on the success of drug development strategies. To remain competitive, companies will need to embrace the rapid innovation in the diagnostic market, utilize diagnostic tools concurrently with research and development, and re-invent how new drugs are brought to market. In this article, specific examples of targeted oncology drugs are used to illustrate the general impact of genetic diagnostics on drug development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Sales and prices of novel oncology therapies (US).

Similar content being viewed by others

References

  1. Collins, F. S. Personalized medicine. The Boston Globe (17 July 2005).

  2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004).

  3. Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukaemia. Science 132, 411–420 (1960).

    Google Scholar 

  4. Fearon E. R. & Volgelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).

    Article  CAS  Google Scholar 

  5. Gleevec US Package Insert. [online],

  6. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).

    Article  CAS  Google Scholar 

  7. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).

    Article  CAS  Google Scholar 

  8. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  9. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).

    Article  CAS  Google Scholar 

  10. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).

    Article  CAS  Google Scholar 

  11. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

    Article  CAS  Google Scholar 

  12. Pegram, M. D., Konecny, G. & Slamon, D. J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 103, 57–75 (2000).

    Article  CAS  Google Scholar 

  13. Surveillance, Epidemiology, and End Results (SEER) Program, Cancer Statistics Review, 1975–2002 [online], (2002).

  14. Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).

    Article  CAS  Google Scholar 

  15. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237–2246 (2003).

    Article  CAS  Google Scholar 

  16. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).

    Article  CAS  Google Scholar 

  17. Press release. Gefitinib (Iressa™) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population [online], (17 December 2004).

  18. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  19. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

    Article  CAS  Google Scholar 

  20. Wingo, P. A. et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J. Natl Cancer Inst. 91, 675–690 (1999).

    Article  CAS  Google Scholar 

  21. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).

    Article  CAS  Google Scholar 

  22. von Bubnoff, N. et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487–491 (2002).

    Article  CAS  Google Scholar 

  23. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472–3475 (2002).

    Article  CAS  Google Scholar 

  24. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).

    Article  CAS  Google Scholar 

  25. Sawyers, C. L. et al. Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase I study. Blood 106, A38 (2005).

  26. Hochhaus, A. et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 'START-C' phase II study. Blood 106, A41 (2005).

  27. Press release. Bristol-Myers Squibb submits new drug application for dasatinib [online], (28 December 2005).

  28. Press release. Genzyme launches exclusive lung cancer test [online], (27 September 2005).

Download references

Acknowledgements

I would like to thank C. I. Rodriguez, T. M, Henrick and J. E. Miller for helpful comments and discussion in reviewing this manuscript

Author information

Authors and Affiliations

  1. Trinity Partners, LLC, 100 Park Avenue, Suite 1600, New York, 10017, New York, USA

    Ryan P. Million

Authors
  1. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

DATABASES

National Cancer Institute

CML

NSCLC

FURTHER INFORMATION

American Society of Clinical Oncology

American Society of Hematology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Million, R. Impact of genetic diagnostics on drug development strategy. Nat Rev Drug Discov 5, 459–462 (2006). https://doi.org/10.1038/nrd2034

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2034

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing